PFG Investments LLC boosted its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) by 28.4% during the 1st quarter, Holdings Channel reports. The fund owned 45,259 shares of the biopharma… [+3999 chars]...
Read moreFortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.78… [+3566 chars]...
Read moreCambridge Investment Research Advisors Inc. grew its position in Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) by 8.7% in the 1st quarter, according to its most recent filing with the Securities… [+3870 chars]...
Read morePayer coverage for Emrosi now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SC… [+10467 chars]...
Read moreIn an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting… [+8652 chars]...
Read moreSCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (Journey Medical or the Company, we, or our), a commercial-stage pharmaceutical company that primarily … [+9772 chars]...
Read more